Investor Centre
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
57.21p
0.500p
at 17-10-2018 3:07:01
15 minute delayed share price from London Stock Exchange provided by Euroland.
